Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US
OBJECTIVE: The purpose of this study was to estimate the long-term cost-utility of treating type 2 diabetes mellitus (T2DM) patients with exenatide once weekly (EQW) compared with insulin glargine (IG) from a US payer perspective.
METHODS: A validated computer simulation model, the CORE Diabetes Model, was used to project lifetime clinical outcomes and direct medical costs. Direct medical costs included pharmacy costs and costs associated with the management of diabetes and its complications. The model was populated using patient characteristics (mean age: 57.9 years; mean diabetes duration: 7.9 years; mean HbA1(c): 8.3%; mean body mass index [BMI]: 32.3 kg/m(2)) and clinical data from a phase 3 clinical trial that compared EQW with IG in T2DM patients on a background of metformin alone or a combination of metformin and a sulphonylurea (DURATION-3). All EQW patients were assumed to have stayed on treatment for 3 years before switching to IG. Health outcomes and costs were discounted at 3% per year. Complication costs were derived from published sources. A range of sensitivity analyses was performed.
RESULTS: Over a lifetime horizon, and compared with IG, EQW was associated with an incremental cost of $3914 (SD = 2923). EQW was projected to increase life expectancy by 0.135 (SD = 0.216) years and to improve quality-adjusted life expectancy by 0.246 (SD = 0.147) quality-adjusted life years (QALYs), generating an incremental cost-effectiveness ratio (ICER) of $15,936/QALY. Assuming a payer's willingness to pay threshold of $50,000/QALY, EQW is therefore cost-effective compared to IG. One-way and probabilistic sensitivity analyses confirmed EQW's cost-effective profile.
LIMITATIONS: Short-term changes (26 weeks) in surrogate end-points (e.g., HbA1(c,) weight, complications) from one clinical trial were used to project long-term future effects on clinical outcomes.
CONCLUSIONS: Treatment with EQW is projected to be cost-effective compared to treatment with IG.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 Suppl 2 |
|---|---|
| Enthalten in: |
Journal of medical economics - 15 Suppl 2(2012) vom: 15., Seite 6-13 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Samyshkin, Yevgeniy [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2ZM8CX04RZ |
|---|
| Anmerkungen: |
Date Completed 12.03.2013 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3111/13696998.2012.708691 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM219406839 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM219406839 | ||
| 003 | DE-627 | ||
| 005 | 20231224042841.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3111/13696998.2012.708691 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0731.xml |
| 035 | |a (DE-627)NLM219406839 | ||
| 035 | |a (NLM)22793669 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Samyshkin, Yevgeniy |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.03.2013 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: The purpose of this study was to estimate the long-term cost-utility of treating type 2 diabetes mellitus (T2DM) patients with exenatide once weekly (EQW) compared with insulin glargine (IG) from a US payer perspective | ||
| 520 | |a METHODS: A validated computer simulation model, the CORE Diabetes Model, was used to project lifetime clinical outcomes and direct medical costs. Direct medical costs included pharmacy costs and costs associated with the management of diabetes and its complications. The model was populated using patient characteristics (mean age: 57.9 years; mean diabetes duration: 7.9 years; mean HbA1(c): 8.3%; mean body mass index [BMI]: 32.3 kg/m(2)) and clinical data from a phase 3 clinical trial that compared EQW with IG in T2DM patients on a background of metformin alone or a combination of metformin and a sulphonylurea (DURATION-3). All EQW patients were assumed to have stayed on treatment for 3 years before switching to IG. Health outcomes and costs were discounted at 3% per year. Complication costs were derived from published sources. A range of sensitivity analyses was performed | ||
| 520 | |a RESULTS: Over a lifetime horizon, and compared with IG, EQW was associated with an incremental cost of $3914 (SD = 2923). EQW was projected to increase life expectancy by 0.135 (SD = 0.216) years and to improve quality-adjusted life expectancy by 0.246 (SD = 0.147) quality-adjusted life years (QALYs), generating an incremental cost-effectiveness ratio (ICER) of $15,936/QALY. Assuming a payer's willingness to pay threshold of $50,000/QALY, EQW is therefore cost-effective compared to IG. One-way and probabilistic sensitivity analyses confirmed EQW's cost-effective profile | ||
| 520 | |a LIMITATIONS: Short-term changes (26 weeks) in surrogate end-points (e.g., HbA1(c,) weight, complications) from one clinical trial were used to project long-term future effects on clinical outcomes | ||
| 520 | |a CONCLUSIONS: Treatment with EQW is projected to be cost-effective compared to treatment with IG | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Glycated Hemoglobin A |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Insulin, Long-Acting |2 NLM | |
| 650 | 7 | |a Peptides |2 NLM | |
| 650 | 7 | |a Venoms |2 NLM | |
| 650 | 7 | |a Insulin Glargine |2 NLM | |
| 650 | 7 | |a 2ZM8CX04RZ |2 NLM | |
| 650 | 7 | |a Exenatide |2 NLM | |
| 650 | 7 | |a 9P1872D4OL |2 NLM | |
| 700 | 1 | |a Guillermin, Anne-Laure |e verfasserin |4 aut | |
| 700 | 1 | |a Best, Jennie H |e verfasserin |4 aut | |
| 700 | 1 | |a Brunell, Steven C |e verfasserin |4 aut | |
| 700 | 1 | |a Lloyd, Adam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical economics |d 1999 |g 15 Suppl 2(2012) vom: 15., Seite 6-13 |w (DE-627)NLM098274902 |x 1941-837X |7 nnns |
| 773 | 1 | 8 | |g volume:15 Suppl 2 |g year:2012 |g day:15 |g pages:6-13 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3111/13696998.2012.708691 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 Suppl 2 |j 2012 |b 15 |h 6-13 | ||